Loading…
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-438M | $-446M | $-424M | -45.9% | - | - |
| 2024 | $0M | $-316M | $-317M | $-295M | -50.4% | - | - |
| 2023 | $0M | $-234M | $-236M | $-189M | -258.4% | - | - |
| 2022 | $0M | $-169M | $-168M | $-157M | -66.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 170.96 | 242.16 | 343.89 | 468.18 |
| Operating Income | -170.96 | -242.16 | -343.89 | -468.18 |
| EBITDA | -169.28 | -234.26 | -315.75 | -437.97 |
| EBIT | -170.96 | -235.94 | -317.42 | -440.02 |
| Pretax Income | -168.10 | -235.94 | -317.42 | -446.21 |
| Net Income | -168.10 | -235.94 | -317.42 | -446.21 |
| Net Income Common Stockholders | -168.10 | -235.94 | -317.42 | -446.21 |
| Total Expenses | 170.96 | 242.16 | 343.89 | 468.18 |
| Interest Expense | 0 | 0 | 0 | 6.19 |
| Interest Income | 2.92 | 7.64 | 26.92 | 29.86 |
| Research And Development | 142.76 | 210.76 | 281.41 | 398.33 |
| Selling General And Administration | 28.20 | 31.40 | 62.48 | 69.85 |
| Normalized EBITDA | -169.28 | -234.26 | -315.75 | -437.97 |
| Normalized Income | -168.10 | -235.94 | -317.42 | -446.21 |
| Basic EPS | -3.23 | -3.95 | -3.37 | 0 |
| Diluted EPS | -3.23 | -3.95 | -3.37 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -168.10 | -235.94 | -317.42 | -446.21 |
| Reconciled Depreciation | 1.68 | 1.67 | 1.67 | 2.05 |
| Net Interest Income | 2.92 | 7.64 | 26.92 | 23.67 |
| Net Income From Continuing And Discontinued Operation | -168.10 | -235.94 | -317.42 | -446.21 |
| Total Operating Income As Reported | -170.96 | -242.16 | -343.89 | -468.18 |
| Diluted Average Shares | 51.98 | 59.68 | 94.14 | 0 |
| Basic Average Shares | 51.98 | 59.68 | 94.14 | 0 |
| Diluted NI Availto Com Stockholders | -168.10 | -235.94 | -317.42 | -446.21 |
| Net Income Including Noncontrolling Interests | -168.10 | -235.94 | -317.42 | -446.21 |
| Net Income Continuous Operations | -168.10 | -235.94 | -317.42 | -446.21 |
| Other Income Expense | -0.05 | -1.42 | -0.45 | -1.70 |
| Other Non Operating Income Expenses | -0.05 | -1.42 | -0.45 | -1.70 |
| Net Non Operating Interest Income Expense | 2.92 | 7.64 | 26.92 | 23.67 |
| Interest Expense Non Operating | 0 | 0 | 0 | 6.19 |
| Interest Income Non Operating | 2.92 | 7.64 | 26.92 | 29.86 |
| General And Administrative Expense | 28.20 | 31.40 | 62.48 | 69.85 |
| Other Gand A | 28.20 | 31.40 | 22.81 | 31.33 |
| Salaries And Wages | 14.75 | 18.02 | 39.67 | 38.52 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Dyne Therapeutics, Inc.this co. | DYN | $2.9B | - | 2.95 | -45.9% | -4.14 |
| Beam Therapeutics Inc. | BEAM | $3.0B | - | 2.35 | -6.5% | -5.05 |
| Denali Therapeutics Inc. | DNLI | $3.0B | - | 2.87 | -50.6% | -3.93 |
| Alumis Inc. | ALMS | $2.9B | - | 7.95 | -80.8% | -6.02 |
| LifeStance Health Group, Inc. | LFST | $2.9B | 371.50 |
| 1.90 |
| 0.6% |
| 39.06 |
| Erasca, Inc. | ERAS | $2.8B | - | 7.96 | -38.3% | -20.28 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.8B | - | 14.56 | -8.5% | -352.93 |
| Haemonetics Corporation | HAE | $2.7B | 16.26 | 3.03 | 20.4% | 9.88 |
| Soleno Therapeutics, Inc. | SLNO | $2.7B | 135.33 | 6.13 | 4.6% | 145.68 |
| Peer Median | - | 135.33 | 4.58 | -7.5% | -4.49 | |